Showing 1 - 20 results of 24,982 for search '(( 1 a decrease ) OR ((( _ large decrease ) OR ( _ ((nn decrease) OR (small decrease)) ))))', query time: 0.99s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

    Image 1_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif by Ying Ye (72583)

    Published 2025
    “…Almost all the TAAbs applied for diagnosis are those elevated, however, there are still large numbers of autoantibodies detected to decrease in tumor serums, and their functions were rarely known. …”
  6. 6
  7. 7
  8. 8

    <b>The loss of insulin-positive cell clusters precedes the decrease of islet frequency and beta cell area in type 1 diabetes</b> by Denise M. Drotar (21679539)

    Published 2025
    “…Insulin-positive (INS+) single cells (≤10µm), cell clusters (>10 to <35µm), small- and medium-sized islets (35-100µm and 100-200µm) were significantly lost at type 1 diabetes onset, while large INS+ islets (>200µm) were preserved. …”
  9. 9

    Why does task performance decrease with burst length? by Swathi Anil (17382903)

    Published 2025
    “…<p>Explanation of why accuracy decreases for methods that do not use temporal information (<i>LF</i>, <i>NLF</i>) as <i>k</i> increases. …”
  10. 10
  11. 11

    Table 1_Effect of decreased suspended sediment content on chlorophyll-a in Dongting Lake, China.docx by Le Zhang (88249)

    Published 2025
    “…The findings provide valuable scientific insights for large-scale lake water quality monitoring and offer critical reference points for future water quality management strategies.…”
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18

    ECoG timescales decrease during spatial attention. by Isabel Raposo (21615517)

    Published 2025
    “…If power was above the threshold (<i>z</i> > 1.96) for a minimum of 10% of the time window (500 ms) after the cue, the channel was considered hemifield-selective. …”
  19. 19
  20. 20

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”